Rehmann Capital Advisory Group Has $6.11 Million Holdings in Johnson & Johnson $JNJ

Rehmann Capital Advisory Group lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,987 shares of the company’s stock after selling 1,129 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Johnson & Johnson were worth $6,108,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. GFG Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the 1st quarter worth about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson during the 1st quarter worth about $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JNJ. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Bank of America raised their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Finally, Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Trading Up 0.5%

Johnson & Johnson stock opened at $192.81 on Thursday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market capitalization of $464.35 billion, a P/E ratio of 18.61, a PEG ratio of 2.25 and a beta of 0.40. The stock has a 50-day simple moving average of $181.64 and a 200 day simple moving average of $165.56.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.